Microbix Biosystems (TSE:MBX) Sets New 12-Month High – Here’s What Happened

Microbix Biosystems Inc. (TSE:MBX) hit a new 52-week high on Wednesday . The company traded as high as C$0.32 and last traded at C$0.31, with a volume of 22000 shares changing hands. The stock had previously closed at C$0.31.

Microbix Biosystems Price Performance

The company has a market cap of C$42.63 million, a P/E ratio of -7.56 and a beta of 0.72. The stock has a 50-day moving average of C$0.30 and a two-hundred day moving average of C$0.26. The company has a debt-to-equity ratio of 27.03, a quick ratio of 5.57 and a current ratio of 5.35.

Microbix Biosystems (TSE:MBX) last issued its quarterly earnings results on Thursday, May 14th. The company reported C($0.01) EPS for the quarter. The business had revenue of C$3.38 million for the quarter. Microbix Biosystems had a negative net margin of 38.62% and a negative return on equity of 21.02%. On average, research analysts anticipate that Microbix Biosystems Inc. will post 0.02 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director Martin Marino acquired 115,000 shares of the stock in a transaction on Thursday, May 28th. The stock was purchased at an average price of C$0.28 per share, for a total transaction of C$32,200.00. Following the completion of the transaction, the director owned 2,000,167 shares of the company’s stock, valued at C$560,046.76. This trade represents a 6.10% increase in their position. Over the last 90 days, insiders purchased 251,000 shares of company stock valued at $68,355. 14.00% of the stock is owned by insiders.

Microbix Biosystems Company Profile

Microbix Biosystems Inc creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.6 million in its last reported fiscal year (2025). It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs ¿ ) and reference materials (QUANTDx ¿ ) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows.